Lebogang Ramma

Using Top‐down and Bottom‐up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale

Lucy Cunnama, Edina Sinanovic, Lebogang Ramma et al. · Health Economics · 2016 · 130 citations · Full text

Pharmacy, Economics, Pharmacoeconomics +17

Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation

Anna Vassall, Mariana Siapka, Nicola Foster et al. · The Lancet Global Health · 2017 · 71 citations · Full text

Pharmacy, Health Sciences, Pharmacoeconomics +17

Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa

Lebogang Ramma, Helen Cox, Lynne Wilkinson et al. · The International Journal of Tuberculosis and Lung Disease · 2015 · 69 citations · Full text

Public Health, Pharmacoeconomics, Clinical Medicine +13

Validity and reliability testing of the Toddler and Infant (TANDI) Health Related Quality of Life instrument for very young children

Janine Verstraete, Lebogang Ramma, Jennifer Jelsma · Journal of Patient-Reported Outcomes · 2020 · 56 citations · Full text

Pharmacy, Child Health, Pediatrics +17

Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa

Edina Sinanovic, Lebogang Ramma, Anna Vassall et al. · The International Journal of Tuberculosis and Lung Disease · 2015 · 52 citations

Pharmacy, Health Policy, Pharmacoeconomics +17